Immune-modulator may be first oral MS drug
NEW YORK A study published in The Lancet Saturday has found that an immune-modulating drug can reduce the number of brain lesions associated with multiple sclerosis.
An international team of scientists conducted the study with 306 MS patients who received laquinimod. Patients who received daily doses of 0.6mg experienced reductions in the cumulative number of brain lesions of 40 percent compared to those who received the placebo, while patients receiving 0.3 mg doses did not experience a significant reduction.
Most drugs to treat MS are injected, but laquinimod is administered orally. Active Biotech is developing the drug, which entered phase III testing last June.
ShopKo to open in-store clinics in Wisconsin
MADISON, Wis. Meriter, a provider of healthcare services, has teamed up with ShopKo to open two FastCare clinics in Madison in mid-October.
Meriter’s clinics, which will be located in ShopKo East and ShopKo West, will be staffed by nurse practitioners who can offer treatment for such acute ailments as pink eye, bladder infections and skin rashes. The n.p. can write a prescription, if needed.
“We’re very pleased to provide this service to residents, as well as visitors, to our community,” stated Geoff Priest, Meriter chief medical officer. “Providing quality health care that is convenient, both in hours and location, is very important to us at Meriter.”
Green Bay, Wis.-based Bellin Hospital, in partnership with ShopKo, started the FastCare concept. Since then, they have negotiated partnerships with other health care systems, including ThedaCare in Appleton, Aspirus in Wausau and Olmstead in Rochester, Minn. Others underway include Beaver Dam and one in Waukesha.
Alnylam inks potential $93 million deal with Kyowa Hakko Kogyo
CAMBRIDGE, Mass. Alnylam Pharmaceuticals has signed a collaborative deal with Kyowa Hakko Kogyo, that could be worth as much as $93 million, to develop and market the experimental respiratory drug ALN-RSV01, according to the Associated Press.
ALN-RSV01 is currently in midstage development for respiratory syncytial virus, which can cause severe lower respiratory infections, particularly in infants. Most of Alynlam’s pipeline, though, is still in the preclinical phase of development, with potential candidates for liver cancer, Huntington’s disease, pandemic flu, and cystic fibrosis, among others.
This is the company’s second recent deal. At the end of May, Alnylam signed a research partnership deal with Takeda Pharmaceuticals worth as much as $1 billion.